Venclexta has also been granted five Breakthrough Therapy Designations by the FDA, including two for previously untreated AML. Venclexta/Venclyxto is being developed by AbbVie and Roche.

Venclexta trial deaths force AbbVie, Roche to stop recruiting myeloma patients The treatment achieved blockbuster status in 2020 and generated sales of $2.6 billion last year, an increase of 13% ...

AbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into the treatment-naive chronic lymphocytic leukaemia (CLL) arena.Top-line results from the CLL14 ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click here to find out why RHHBY is a Buy.

Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced risk of disease progression or death by 67% compared to a current standard-of-care Approval for expanded use of Venclexta ...

AbbVie and Roche’s Venclexta has struggled to significantly prolong acute myeloid leukemia (AML) patients’ lives when coupled with a certain type of chemo. But not azacitidine. Adding ...

Venclexta, a BCL-2 inhibitor that AbbVie markets with Roche’s Genentech division, was approved in 2016 for second-line chronic lymphocytic leukemia, or CLL, that harbors a mutation known as ...

Venclexta represents a new treatment option for people with acute myeloid leukaemia regardless of subtypes Basel, 21 November 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US ...

AbbVie and Roche’s long-anticipated combination trial of Venclexta/Venclyxto and Rituxan in chronic lymphocytic leukaemia, setting up regulatory filings for the duo. The phase III MURANO trial pithed ...

Roche's another AML drug, idasanutlin, is researched with cytarabine (phase 3) for R/R AML, with Venclexta for treatment of R/R AML in patients unfit for chemo (Phase 2), and also with cytarabine ...

Roche RHHBY announced that the FDA has granted full approval to leukemia drug, Venclexta, in combination with Vidaza or Dacogen or low-dose cytarabine (LDAC).. The combination has been approved ...

AbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into the treatment-naive chronic lymphocytic leukaemia (CLL) arena.Top-line results from the CLL14 ...